Previous 10 | Next 10 |
home / stock / nvs / nvs articles
Cytokinetics, Incorporated (NASDAQ: CYTK) shares are trading lower on Tuesday, pulling back from Monday strength. What To Know: Cytokinetics stock ...
Cytokinetics Inc (NASDAQ: CYTK) shares are trading higher after a report on potential takeover talks with Novartis AG (NYSE: NVS). T...
Sunday, Exelixis Inc (NASDAQ: EXEL) provided financial guidance for fiscal year 2024 and delivered an update on its business. The co...
Voyager Therapeutics Inc (NASDAQ: VYGR) announced a strategic collaboration and capsid license agreement with Novartis Pharma AG, a subsi...
On Tuesday, Cingulate Inc (NASDAQ: CING) received FDA guidance for CTx-1301 (dexmethylphenidate), its lead investigational prod...
The FDA approved Calliditas Therapeutics AB's (NASDAQ: CALT) Tarpeyo (budesonide) delayed-release capsules to reduce the loss of kidn...
RBC Capital Markets initiated coverage on Fusion Pharmaceuticals Inc (NASDAQ: FUSN), saying the radiopharmaceutical industry is a bu...
Monday, Lantheus Holdings Inc (NASDAQ: LNTH) and POINT Biopharma Global Inc (NASDAQ: PNT) reported topline data from pivot...
The FDA approved Merck & Co Inc's (NYSE: MRK) Welireg (belzutifan), an oral hypoxia-inducible factor-2 alpha (HIF-2α) inhib...
News, Short Squeeze, Breakout and More Instantly...
2024-07-18 09:38:21 ET The stock market is a place where investors buy and sell shares of publicly traded companies. It offers opportunities for individuals and institutions to invest in various sectors of the economy. The market’s performance is influenced by economic conditions, co...
2024-07-18 04:59:00 ET Some might hesitate to invest in stocks during a bull run, like the one we are experiencing. They argue that equities are likely to be overvalued. However, it's possible to find reasonably valued picks in this environment, even among top high-quality stocks. And some ...
2024-07-12 13:15:04 ET Morgan Stanley analyst issues EQUAL-WEIGHT recommendation for NVS on July 12, 2024 11:58AM ET. The previous analyst recommendation was Equal-Weight. NVS was trading at $111.855 at issue of the analyst recommendation. The overall analyst consensus :...